TC BioPharm
Holytown
About TC BioPharm
TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors. TC BioPharm’s mission is to develop and commercialize innovative cell-based products to treat disease, improving patient health and quality of life. TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders, including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $68.6M
- Funding stage: IPO
- Last round: Grant (Nov 2024)
- Ticker: nasdaq:TCBP
- Website: tcbiopharm.com
- Phone: +4401414337557
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tc-biopharm-39624 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.